Inhibitor of DNA-binding-1 (ID1) transcription factor is essential for the proliferation and progression of many cancer types including leukemia. However, the ID1 protein has not yet been therapeutically targeted in leukemia. ID1 is normally polyubiquitinated and degraded by the proteasome. Recently, it has been shown that USP1, a ubiquitin specific protease, deubiquitinates ID1 and rescues it from proteasome degradation. Inhibition of USP1 therefore offers a new avenue to target ID1 in cancer. Here, using a Ubiquitin-Rhodamine-based high throughput screening, we identified small molecule inhibitors of USP1 and investigated their therapeutic potential for leukemia. These inhibitors blocked the deubiquitinating enzyme activity of USP1 in vitro in a dose-dependent manner with an IC 50 in the high nanomolar range. USP1 inhibitors promoted the degradation of ID1 and, concurrently, inhibited the growth of leukemic cell lines in a dose dependent manner. A known USP1 inhibitor, Pimozide, also promoted ID1 degradation and inhibited growth of leukemic cells. In addition, the growth of primary Acute Myeloid Leukemia (AML) patient-derived leukemic cells was inhibited by a USP1 inhibitor. Collectively, these results indicate that the novel small molecule inhibitors of USP1 promote ID1 degradation and are cytotoxic to leukemic cells. The identification of USP1 inhibitors therefore opens up a new approach for leukemia therapy.
INTRODUCTION
ID1 (inhibitor of DNA binding 1) protein is a member of the helix-loop-helix (HLH) family of transcriptional regulatory proteins which consists of four members, ID1-ID4 (1, 2) . Basic HLH (bHLH)-family of transcription factors are key regulators of cellular development and differentiation. The bHLH proteins (e.g. E2A, E2-2, HEB) form homodimers or heterodimers with other tissue-specific bHLH proteins (e.g. MyoD, SCL/tal1), bind DNA upon dimerization, 4 and activate transcription of differentiation-associated proteins. The ID-family of HLH proteins can also form dimers with bHLH proteins (3) . However, the ID-bHLH heterodimers are transcriptionally inactive and are unable to bind to the DNA since ID proteins lack a basic DNA binding domain (2) . Accordingly, ID proteins antagonize the functions of bHLH proteins and inhibit the bHLH protein-mediated transactivation of genes which promote cellular differentiation. ID proteins, therefore, are also termed inhibitors of differentiation. In addition to binding to the bHLH proteins, ID proteins can also interact with non-bHLH proteins and antagonize their function (4) . ID1, one of the ID proteins, is known to play a role in cellular transformation. It is overexpressed in a variety of human cancer types, including pancreatic, cervical, ovarian, prostate, breast, colon and brain cancer (5) (6) (7) (8) (9) (10) (11) . In most of these cancer types, high ID1 expression correlates with poor prognosis and increased chemoresistance (7, 9, 10, 12, 13) .
Moreover, functional studies have demonstrated that ID1 can promote cell proliferation, inhibit differentiation, delay cellular senescence in primary human cells, and promote cell migration and the metastatic phenotype of cancers (14) . ID1 function is also required for maintaining the 'stemness" of many normal and malignant tissues (10, 11, 15) .
Recent studies indicate that ID1 is also an activator of leukemic cell growth. First, Tang et al (16) observed high levels of ID1 expression in primary AML samples, and high expression correlated with poor prognosis. Second, ID1 was identified as a common downstream target of constitutively activated oncogenic tyrosine kinases, such as BCR-ABL and TEL-ABL (17) .
Third, ID1 can immortalize hematopoietic progenitors in vitro and promote a myeloproliferative disease in mice in vivo (18) . Moreover, knockdown of ID1 expression inhibited leukemic cell growth (18) . Collectively, these observations suggest that ID1 is a prime therapeutic target for (14) . Protein-protein interactions in the nucleus, such as the interaction of ID1 with HLH factors, are notoriously difficult to inhibit with small molecules (19) .
A recent report offers an alternative strategy for knocking down the ID1 protein-namely, through inhibition of the ubiquitin specific protease, USP1 (20) . USP1 is a deubiquitinating (DUB) enzyme, which removes polyubiquitin chains from the ID1 protein (20) . ID1 is normally polyubiquitinated and rapidly degraded by the proteasome (21) (22) (23) . USP1 removes the polyubiquitin chains and rescues ID1 from degradation. Selectively knocking down USP1 using shRNA results in a rapid degradation of ID1 in osteosarcoma cells. Importantly, USP1
knockdown results in decreased mesenchymal cell proliferation, and enhanced differentiation of osteosarcoma cells which overexpress USP1 and ID1 (20) , providing a rationale for differentiation therapy of many cancer types including leukemia (e.g. acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML)). We therefore reasoned that pharmacologic inhibition of USP1 would promote ubiquitin-mediated degradation of ID1 protein, resulting in differentiation and growth inhibition of immature leukemic cells. Our laboratory has previously shown that human USP1 forms a stable complex with its binding partner, USP1 associated factor 1 (UAF1) (24) . USP1 by itself exhibits low DUB activity; however, this activity is significantly enhanced when bound as a USP1/UAF1 complex. Using high throughput screening, we identified a small molecule inhibitor of the USP1/UAF1 complex. We describe here a novel small molecule (C527), and multiple derivatives, that inhibit USP1 catalytic activity, promote ID1 degradation, and inhibit leukemic cell growth. 
MATERIAL AND METHODS

High Throughput Screening
The USP1/UAF1 complex was prepared as described previously (24) (Figure 1 ) and the protein complex was used for high throughput screening. The fluorogenic ubiquitin-Rhodamine (UbRhodamine) based enzyme assay was established in a 384-well format for high throughput screening. The reaction buffer containing free ubiquitin and USP1/UAF1 enzyme complex was added in 384 well plates using automated liquid handling robot-Bio-Tek Microfill (Bio-Tek Instrments Inc., VT), followed by addition of the compounds (in DMSO) from the compound library plates to wells using a pin transfer robotic system at a final concentration of 10 µM. The reactions were then incubated for 30 min at room temperature followed by the addition of UbRhodamine to initiate the reactions. The enzyme activity of the USP1/UAF1 complex was determined by measuring the fluorescence of Ub-Rhodamine. 150,000 compounds were screened from the library plates at the Partners Center for Drug Discovery, Cambridge, MA. Details of the screen are provided in the 'supplementary methods" section.
In Vitro Deubiquitination Assays
Purified USP5 enzyme was purchased from Boston Biochem. UCH-L1 and UCH-L3 were as reported previously (25) . USP12/46 was prepared in our laboratory as described (26, 27) . The in vitro enzymatic assays were performed as described previously (24) using ubiquitin-AMC (Ub-7-amido-4methylcoumarin; Boston Biochem) as a substrate in a reaction buffer containing 20 mM HEPES-KOH (pH 7.8), 20 mM NaCl, 0.1 mg/ml ovalbumin, 0.5 mM EDTA and 10 mM dithiothreitol. The fluorescence was measured by FluoStar Galaxy Fluorometer (BMG Labtech).
For the Ub-vinylsulfone (VS) assay, the proteins were incubated with Ub-VS (Boston Biochem) at 0.5 µM final concentration for 45 min at 30 °C, followed by the immunoblotting analysis. 
Homologous recombination (HR) analysis and immunofluorescence
HR activity was analyzed by DR-GFP reporter as previously described (29) . U2OS-DRGFP cells 
RESULTS
Identification of a novel USP1 inhibitor using high throughput screening
We have previously reported that USP1 by itself exhibits poor DUB activity. However, when bound to its interacting partner, UAF1, the catalytic activity of USP1 is significantly enhanced (24) . We therefore utilized a purified USP1/UAF1 complex and performed a high throughput screen to identify a USP1 inhibitors ( Figure 1 ). We used the cDNA encoding a full length USP1 polypeptide, which had a substitution of GG to AA at amino acid residues 670 to 671 ( Figure   1A ). We have previously shown that this amino acid change disrupts an autocleavage site in USP1 but does not alter the interaction of USP1 with UAF1 or the DUB activity of the complex (24, 31) . Human USP1 (with GG to AA mutation) and UAF1 proteins were coexpressed in SF9 insect cells to generate a protein complex with elevated DUB activity. The USP1/UAF1 protein complex was purified and the purity was confirmed by coomassie staining ( Figure 1B ). The stable USP1/UAF1 enzyme complex was then subjected to a high throughput inhibitor screen, described schematically in Figure 1C . A small molecule, C527 (heterocyclic tricyclic 1,4-dihydro-1,4-dioxo-1H-naphthalene) ( Figure 1D ) was identified which inhibited the USP1/UAF1 complex. 
USP1 inhibitor C527 has a high affinity for USP1.
We next confirmed the ability of C527 to inhibit the USP1/UAF1 complex in a dose-dependent and time-dependent manner, using Ub-AMC as a substrate ( Figure 1E -G). Pretreatment of USP1/UAF1 with C527 resulted in inhibition of its enzyme activity with an IC 50 of 0.88 ± 0.03 μM. To determine the specificity of C527 in USP1/UAF1 inhibition, we next examined its ability to inhibit other DUB enzymes in vitro. UAF1 stimulates not only USP1, but also two other DUB enzymes, USP12 and USP46 (26) . We therefore tested C527 for its ability to inhibit the purified USP12/USP46 complex or other DUBs. C527 inhibited the DUB activity of the USP12/USP46 complex and other DUB enzymes in vitro. However, the IC 50 of C527 for these DUB enzymes was higher in comparison to USP1/UAF1 complex ( Table 1 ). C527 had considerably less inhibitory effect on UCH-L1 and UCH-L3, a different subclass of deubiquitinating enzymes, referred to as the ubiquitin C-terminal hydrolases (25) , even though they are also cysteine proteases. Taken together, C527 is a pan-deubiquitinating enzyme inhibitor in vitro, with a high nanomolar IC 50 for the USP1/UAF1 complex.
In order to generate a USP1 inhibitor with improved cellular potency, we chemically synthesized several analogs/derivatives of C527 and determined their IC 50 for USP1/UAF1 inhibition (data not shown). We then selected a derivative, SJB2-043 (IC 50 =0.544 µM), for further studies due to the feasibility of its large-scale chemical synthesis.
USP1 inhibitor SJB2-043 inhibits the enzyme activity of native USP1
We next determined whether SJB2-043 inhibits the DUB activity of native USP1 complexes isolated from human cells (Figure 1 H, I ). For this purpose, we performed competition assays between SJB2-043 and the ubiquitin (Ub) active site probe HA-Ub-Vinyl sulfone (HA-Ub-VS) Figure 1H ). This affinity reagent covalently modifies and traps active DUB enzymes in cell extracts (32) . Cells were treated with SJB2-043 for 24 hrs and cell extracts were incubated with HA-Ub-VS, followed by immunoblotting with anti-USP1 or anti-HA antibodies. Consistent with our previous studies and the most recent studies by Piatkov et al (24, 31, 33) , USP1 in the untreated cells was detected on western blot as a doublet; full length USP1 and an auto-cleaved USP1 with only N-terminus ( Figure 1I, lane 1) . The Ub-USP1 conjugates were generated in the untreated cell lysates and were detected by an increase in molecular weight of USP1 ( Figure 1I , lane 2). However, the formation of the Ub-USP1 conjugate was inhibited by the addition of SJB2-043 (lanes 4). Ub-aldehyde, a potent known nonspecific DUB inhibitor, caused a complete loss of USP1-Ub-VS conjugates in this competition assay (lane 3). SJB2-043 inhibited the Ub-VS labeling of a limited number of endogenous DUB enzymes ( Figure 1I , anti-HA blot). In addition, SJB2-043 inhibited the labeling of USP1 with Ub-VS in a dose dependent manner (supplementary figure 1A) . Taken together, these data demonstrate that SJB2-043 is an inhibitor of the native USP1/UAF1 complex.
Novel USP1 inhibitors promote degradation of ID1 in leukemic cells
shRNA knockdown of USP1 results in enhanced proteasome-mediated degradation of ID1 in osteosarcoma cells (20) . ID1 degradation in osteosarcoma cells results in mesenchymal differentiation and decreased cell proliferation. We therefore tested whether small molecule USP1 inhibitors enhance ID1 degradation in cells. Indeed, USP1 inhibitor C527 promoted the dose-dependent degradation of ID1 in human U20S osteosarcoma cells (data not shown). We Figure 2C, supplementary figure 1B ).
SJB2-043 also caused a decrease in the levels of other ID proteins, namely ID2 and ID3 in K562 cells (supplementary figure 1C) . To determine whether the decrease in ID1 levels was secondary to a decrease in USP1 levels, we next generated a K562 stably transfected with a cDNA encoding doxycycline-induced shRNA to USP1. As expected, doxycycline exposure of these cells resulted in a dose-dependent decrease in USP1 expression (supplementary figure 2A) .
Moreover, depletion of USP1 by siRNA promoted ID1 degradation in K562 cells (supplementary figure 2B) . Importantly, siRNA-mediated knockdown of USP1 in leukemic K562 cells resulted in growth inhibition, increased apoptosis and cell cycle arrest (Supplementary figures 2C, 2D, 2E, 2F) . Collectively, these results indicated that while SJB2-043 may have off target effects, it exhibits its activity in K562 cells at least in part by promoting degradation of USP1 which results in ID1-ID3 degradation.
USP1 inhibitors are cytotoxic to leukemic cells
We next determined whether the USP1 inhibitors are cytotoxic to leukemic cells and whether the cytotoxicity results from ID1 degradation. K562 leukemic cells were treated with SJB2-043, and survival and differentiation were assessed. SJB2-043 caused a dose-dependent decrease in the number of viable K562 cells, with an EC 50 In order to determine if the cytotoxicity of the USP1 inhibitor was due to USP1/ID1 degradation, we next evaluated analogs of SJB2-043 in leukemic cells (Supplementary Figure 3) .
The USP1 inhibitor analogs (e.g. SJB2-127) with no significant activity on USP1 (IC 50 >10 μM ) or ID1 degradation at concentrations upto 10 μΜ, did not exhibit cytotoxic effects on leukemic cells (supplementary figure 3A) . The analog SJB2-109 had comparable biochemical inhibitory activity (IC 50 =0.416 μM ) to our lead inhibitor SJB2-043 and exhibits comparable effects on ID1 degradation and leukemic cell survival. Importantly, a more potent analog SJB3-019A (IC 50 = 0.0781 μM) was 5 times more potent than SJB2-043 in promoting ID1 degradation and cytoxicity in K562 cells.
To determine whether ID1 degradation resulted from USP1 inhibition and was not secondary to apoptosis, we next analyzed USP1/ID1 levels and apoptosis after treating K562 Collectively, these results indicated that novel USP1 inhibitors promote ID1 degradation by specifically targeting native USP1 and cause cytotoxicity in multiple leukemic cell lines.
Pimozide, a known USP1 inhibitor, promotes ID1 degradation and inhibits leukemic cell growth
A known drug, Pimozide, is a weak USP1 non-competitive inhibitor (34) . Pimozide may also inhibit STAT5 activation, thereby reducing the survival of BCR/ABL driven CML cells (35) . We Figure 4E , Pimozide treatment caused a modest inhibition of tumor growth. Taken together, Pimozide, a commercially available weak USP1 inhibitor, promotes ID1 degradation and inhibits leukemic cell growth in vitro and in vivo, suggesting that our more potent USP1 inhibitors may have a stronger anti-leukemic effect.
USP1 inhibitor promotes ID1 degradation and inhibits growth of primary AML cells from patients
Human AML precursor cells arise from leukemic stem cells (LSCs) and LSC differentiation is controlled through coordinate transcriptional regulation including the bHLH proteins. We therefore, tested whether the USP1 inhibitor also promotes ID1 degradation and cytoxicity in primary human leukemic cells. Primary fresh bone marrow and peripheral blood samples were acquired from AML patients and mononuclear cells were harvested. The cells were then exposed to USP1 inhibitor for 48-72 hrs in culture and ID1 levels as well as cell viability was determined. USP1 inhibitor SJB2-043 exhibited dose-dependent cytotoxicity on the primary bone marrow as well as peripheral blood from AML patients (Figure 5 A, B) . Moreover, SJB2-043 treatment caused inactivation of USP1 and promoted ID 1 degradation in primary AML cells ( Figure 5C 
USP1 inhibitor increases the levels of Ub-FANCD2 and disrupts the homologous recombination
Previous studies indicate that USP1 has other substrates besides ID1 (36) . For instance, the USP1/UAF1 complex deubiquitinates the cellular monoubiquitinated substrates Ub-FANCD2
and Ub-PCNA (31, 37) . Deubiquitination of FANCD2 is a critical step in the Fanconi anemia (FA)/BRCA DNA repair pathway (38, 39) . Knockout or knockdown of USP1/UAF1 results in cellular hypersensitivity to DNA cross-linking chemotherapy agents such as Mitomycin C (40, 41) . Murine knockout of USP1 results in cellular increase in Ub-FANCD2 and a mouse phenotype resembling FA (41) . Knockout of USP1 also results in elevated levels of Ub-PCNA, leading to an increase in DNA translesion synthesis (TLS) (31).
We next determined whether the USP1 inhibitors can alter cellular levels of Ub-FANCD2, Ub-FANCI, a binding partner of FANCD2 (Figure 6 ). Hela cells were treated with USP1 inhibitor C527 and levels of FANCD2 and FANCI were determined by western blotting of the cell lysates. C527 treatments caused an increase in the levels of Ub-FANCD2 and Ub-FANCI ( Figure 6A ). SJB2-043 (another USP1 inhibitor) also increased the level of Ub-FANCD2 (supplementary figures 6A and 6B ). An increase in Ub-PCNA was also observed in cells exposed to SJB2-043 (supplementary figure 6C) suggesting that besides FANCD2, PCNA is also affected by USP1 inhibition. Hela cells were next pre-treated with C527 followed by the treatment with DNA damaging agents including Mitomyin C, a DNA cross-linking agent. Pretreatment of cells with USP1 inhibitor caused an enhancement in the cytoxicity of Mitomycin C and Camptothecin ( Figure 6B ). Figure 6C) , based on the measurement of cellular GFP in this assay. We also confirmed HR defect by evaluating Rad51 foci formation, another surrogate marker of cellular HR activity ( Figure 6D ). C527 inhibited Camptothecin induced the Rad51 foci in Hela cells. The more active USP1 inhibitor SJB3-019A also increased the levels of Ub-FANCD2 and Ub-PCNA, and decreased the HR activity (supplementary figures 6D-F). Taken together, these results suggest that USP1 inhibitor treatments lead to an increase in ubiquitinated forms of FANCD2 and FANCI, causes a decrease in HR activity, and sensitizes cells to DNA damaging agents.
DISCUSSION:
ID1 is essential for proliferation and maintenance of many cancer types (14, 42) . However, it has not yet been therapeutically targeted with a small molecule in leukemia. Here, we demonstrate that targeting USP1 with a small molecule, can promote ID1 degradation and cell death in multiple leukemic cell lines. Our data demonstrate that ID1 can be targeted even in primary human leukemic cells using novel inhibitors of USP1.
The drug of choice for chronic myelogenous leukemia (CML) is Imitanib, although drug resistance remains a problem. Novel therapies are also needed for the cure of acute myelogenous leukemia (AML), the most common acute leukemias of adults. USP1 inhibitors represent a novel class of drugs for these cancers. USP1 inhibitors can degrade ID1, promote differentiation, and induce apoptosis in these types of leukemic cells and can be potential therapeutic agents. ID1
blocks cellular differentiation at least in part, through its repressive effect on the expression of An inhibitor of USP1, Pimozide, was recently identified (34) . Pimozide, an antipsychotic drug, is currently FDA approved for treatment of Tourrete's syndrome. However, its efficacy in promoting ID1 degradation has not been previously reported. In our studies, Pimozide promotes ID1 degradation and causes cytoxicity in leukemic cells. Our in vivo studies using Pimozide showed a modest decrease in tumor volume in xenograft models of K562 leukemic cells. This is consistent with the recent report by Nelson et al (45) who observed a modest effect of Pimozide in FLT3-AML-driven tumor models. Of note, the EC 50 of Pimozide on leukemic cells is significantly higher than our novel USP1 inhibitors. Even though Pimozide is currently used in humans for the treatment of Tourrete's syndrome, its efficacy in mouse tumor models is limited due to its toxicity. Accordingly, at the maximum tolerated doses, Pimozide may not be an effective anti-cancer agent, at least in leukemic mouse models. Moreover, in addition to exhibiting an inhibitory activity to USP1, it also abrogates STAT5 activity in leukemic cells (35, 45) .
ID1 plays an important role in invasiveness of many cancer types including breast and brain tumors (11, 46, 47) . In summary, we have identified novel small molecule inhibitors of USP1 which exhibit nanomolar IC 50 for USP1 activity. These inhibitors also promote ID1 degradation and cause cytotoxicity in a variety of leukemic cell lines and primary leukemic cells. Further preclinical assessment of these small molecules in mouse models will determine their efficacy as novel anticancer agents. If successful, these newly identified USP1 inhibitors can have broader implications and can be valuable therapeutic agents for not only leukemia but also for other cancer types (e.g. breast cancer and glioblastoma) in which ID1 may be a prime therapeutic target.
ACKNOWLEDGEMENTS:
The authors thank Anna Blachman, Kevin O'Connor, and Benjamin Primack for their technical assistance. The authors also thank Jung Min Kim for her help in generating the data on p21 expression. 
